<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004838.pub2" GROUP_ID="SCHIZ" ID="153804030510220077" MERGED_FROM="" MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 14:57:42 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="NC01" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Nicotine for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="1185259982E26AA201DC7B3E806E7C00" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sumir</FIRST_NAME><LAST_NAME>Punnoose</LAST_NAME><POSITION>SpR in Psychiatry</POSITION><EMAIL_1>sumpear@yahoo.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Seacroft Hospital</DEPARTMENT><ORGANISATION>Newsam Centre</ORGANISATION><ADDRESS_1>York Road</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS14 6WB</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 305 6434</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="1185259982E26AA201DC7B3E806E7C00" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sumir</FIRST_NAME><LAST_NAME>Punnoose</LAST_NAME><POSITION>SpR in Psychiatry</POSITION><EMAIL_1>sumpear@yahoo.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Seacroft Hospital</DEPARTMENT><ORGANISATION>Newsam Centre</ORGANISATION><ADDRESS_1>York Road</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS14 6WB</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 305 6434</PHONE_1></ADDRESS></PERSON><PERSON ID="1184D4E882E26AA201DC7B3EECDF3734" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Madhvi</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Belgamwar</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>madhvirb@yahoo.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Radbourne Unit</DEPARTMENT><ORGANISATION>Royal Derby Hospital</ORGANISATION><ADDRESS_1>Uttoxeter New Road</ADDRESS_1><CITY>Derby</CITY><ZIP>DE22 3WQ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1782 744 099</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-31 10:41:05 +0000" MODIFIED_BY="John  Rathbone" NOTES="&lt;p&gt;Minor update: 2/22/06&lt;/p&gt;" NOTES_MODIFIED="2008-10-31 10:41:05 +0000" NOTES_MODIFIED_BY="John  Rathbone">
<UP_TO_DATE>
<DATE DAY="1" MONTH="9" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="9" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="11" YEAR="2007"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="18" MONTH="1" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:15:34 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Leeds Mental Health Teaching NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>North Staffordshire Combined Mental Health NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-03 14:57:42 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-31 10:43:42 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-31 10:43:42 +0000" MODIFIED_BY="[Empty name]">Nicotine for schizophrenia</TITLE>
<SUMMARY_BODY>
<P>People with schizophrenia tend to smoke heavily and to a greater extent when compared to other patient groups. In this review we aimed to investigate this by searching for good quality evidence from randomised controlled trials on the effect of nicotine for schizophrenia, and/or to ascertain whether nicotine modifies the side effects of antipsychotics. Unfortunately we found no trials that met our inclusion criteria to support or refute this. There is a need for good quality randomised controlled trials that investigate the effects of nicotine for schizophrenia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The proportion of people with schizophrenia who smoke is very high, and as a rule, they tend to be heavier smokers when compared to the general population and those with other psychiatric disorders. Nicotine, the psychoactive component in tobacco, is thought to produce psychological effects that help to alleviate psychotic symptoms.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the effects of nicotine and related products in the treatment of schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We electronically searched the Cochrane Schizophrenia Group's Register (April 2005), supplemented with manually inspecting references of all identified studies and by contacting authors of studies where required.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included all randomised clinical trials comparing nicotine or related products as a sole or adjunctive treatment for people with schizophrenia or other similar serious, non-affective psychotic illness.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Citations and, where possible, abstracts were independently inspected by reviewers and the papers ordered were scrutinised and quality assessed. We extracted and evaluated data independently and analysed on an intention to treat basis. We would have calculated fixed effect relative risk (RR), number needed to treat/harm (NNT/H) and their 95% confidence intervals (CI) for binary outcomes and for continuous non-skewed data we would have calculated weighted mean differences. We would have excluded data if loss to follow-up had been greater than 50% and inspected the data for heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We did not find any trials that met the inclusion criteria.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There ought to be further research of nicotine for schizophrenia by parallel group design randomised controlled trials investigating the effects of nicotine on symptoms of schizophrenia as well as on side effects of antipsychotic drugs. We further note that authors and journals should conform to the CONSORT guidelines when publishing the research articles, especially when disclosing all the data available from a particular study.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-31 10:54:55 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Schizophrenia is a major psychiatric disease with a yearly prevalence of 0.4 to 0.8% (<LINK REF="REF-Dohrenwend-1980" TYPE="REFERENCE">Dohrenwend 1980</LINK>) and a lifetime risk of about 1% (<LINK REF="REF-Regier-1984" TYPE="REFERENCE">Regier 1984</LINK>, <LINK REF="REF-Jablensky-1992" TYPE="REFERENCE">Jablensky 1992</LINK>). Although antipsychotics are generally effective in the treatment of schizophrenia when taken appropriately, compliance is poor and averages at around 50% (<LINK REF="REF-Fenton-1997" TYPE="REFERENCE">Fenton 1997</LINK>, <LINK REF="REF-Young-1986" TYPE="REFERENCE">Young 1986</LINK>). </P>
<P>The proportion of people with schizophrenia who smoke is very high. Figures as high as 88% have been reported (nearly three times that of the general population) and the increased numbers remain prevalent even after adjustments are made for marital status, alcohol use and socio-economic status (<LINK REF="REF-Hughes-1986" TYPE="REFERENCE">Hughes 1986</LINK>, <LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>). This is also the case when compared to other psychiatric diagnoses, with 40% to 50% of people with anxiety and depression using nicotine (<LINK REF="REF-Addington-1998" TYPE="REFERENCE">Addington 1998</LINK>). One study revealed that 68% of people with schizophrenia who smoked were classed as heavy smokers (25 or more cigarettes daily) compared with 11% of the general smoking population (<LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>). Nicotine dependence remains the most widespread substance misuse in people with schizophrenia (<LINK REF="REF-Ziedonis-1997" TYPE="REFERENCE">Ziedonis 1997</LINK>).</P>
<P>So far there have been no systematic reviews examining the use of nicotine for schizophrenia. The aim of this review is to examine and analyze the results from any published research in the topic of nicotine for schizophrenia.</P>
<P>Technical background<BR/>The psychoactive component of tobacco is nicotine. Nicotine affects the CNS by acting as an antagonist at the nicotinic subtype of acetylcholine receptors. About 25% of the nicotine inhaled during smoking reaches the bloodstream. On entering the bloodstream, the nicotine reaches the brain within 15 seconds. The half life of nicotine is approximately two hours. Nicotine is believed to produce its positive reinforcing and addictive properties by activating the dopaminergic pathway projecting from the ventral tegmental area to the cerebral cortex and the limbic system. In addition to activating a dopamine reward system, nicotine causes an increase in the concentrations of circulating norepinephrine and epinephrine and an increase in the release of vasopressin, beta-endorphin, ACTH, and cortisol. These hormones are thought to contribute to the basic stimulatory effects of nicotine on the CNS.</P>
<P>Nicotine augments dopamine release in nucleus accumbens and prefrontal cortex. People with chronic schizophrenia have decreased dopaminergic activity in prefrontal cortex and nicotine induced dopamine release could be seen as a potential physiological antagonist to negative symptoms in schizophrenia (<LINK REF="REF-Glassman-1993" TYPE="REFERENCE">Glassman 1993</LINK>). People with schizophrenia lack attention skills and processing of auditory information is poor. This is due to reduced gating of hippocampal response to repeated auditory stimulation, making filtering out of background noise more difficult. Nicotine transiently improves the sensory gating as assessed by normalization of P50 during auditory evoked potentials, implying that smoking will alleviate difficulties with processing of sensory information in schizophrenia (<LINK REF="REF-Adler-1993" TYPE="REFERENCE">Adler 1993</LINK>). Low smoking cessation rates in those with schizophrenia, in conjunction with reports that some smokers with schizophrenia experience an acute increase in psychotic symptoms during attempts to quit smoking, favour a self-medication model.</P>
<P>Nicotine present in tobacco (Nicotiana tabacum <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) increases cortical release of acetylcholine. This causes electro-cortical arousal, which results in 'stress reduction' as perceived by people using nicotine related products.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine the effects of nicotine and related products in the treatment of schizophrenia or related psychoses, in comparison with placebo, no treatment or antipsychotic medication.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-31 10:52:19 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-31 10:52:19 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. Where a trial was described as 'double-blind' but it was implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials were and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with schizophrenia, schizophreniform psychosis and schizophrenia-like illnesses, diagnosed by any criteria, were included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Nicotine and tobacco in any dose or combination prescribed either on their own or in combination with antipsychotic drugs, compared to placebo or antipsychotic drugs.</P>
<P>2. Placebo or no treatment</P>
<P>3. Antipsychotic drugs produced by pharmaceutical companies: any compound, dose, pattern or means of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-31 10:52:19 +0000" MODIFIED_BY="[Empty name]">
<P>We divided outcomes into short-term (less than three months), medium term (3-12 months) and long term (more than one year).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-31 10:49:03 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clinical response<BR/>1.1 Clinical significant response in global state</P>
<P>2. Other adverse effects, general and specific</P>
<P>3. Service utilization outcomes<BR/>3.1 Hospital admission</P>
<P>4. Quality of life/satisfaction with care for either recipients of care or careers<BR/>4.1 Significant change in quality of life/satisfaction</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-31 10:49:27 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clinical response<BR/>1.1 Average score in global state<BR/>1.2 Clinical significant response on general psychotic symptoms<BR/>1.3 Average score in psychotic symptoms<BR/>1.4 Clinical significant response in positive symptoms<BR/>1.5 Average score in positive symptoms<BR/>1.6 Clinical significant response in negative symptoms<BR/>1.7 Average score in negative symptoms<BR/>1.8 Use of additional medication for psychiatric symptoms</P>
<P>2. Extrapyramidal side effects<BR/>2.1 Movement disorders<BR/>2.2 Incidence of use of antiparkinson drugs<BR/>2.3 Average score/change in extrapyramidal side effects - including extrapyramidal effects</P>
<P>3. Service utilization outcomes<BR/>3.1 Days in hospital<BR/>3.2 Times of relapse</P>
<P>4. Quality of life/satisfaction with care for either recipients of care or careers<BR/>4.1 Average score/change in quality of life/satisfaction</P>
<P>5. Leaving the study early</P>
<P>6. Death, suicide or natural causes</P>
<P>7. Economic outcomes</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-31 10:46:37 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-31 10:46:00 +0000" MODIFIED_BY="[Empty name]">
<P>1. We searched The Cochrane Schizophrenia Group's study-based Register (April 2004) using the phrase:</P>
<P>[(*nicotin* OR *nicotiana* OR *smoking* OR *tobacc* OR *cigar*) in REFERENCE and (nicotin* OR smoking* OR *tobacc* OR *cigar*) in STUDY)]<BR/>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-31 10:46:37 +0000" MODIFIED_BY="[Empty name]">
<P>1. Hand search</P>
<P>We searched conference abstracts for further studies.</P>
<P>3. Reference lists<BR/>We also inspected the references of all identified studies (included and excluded) for further relevant trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Study selection<BR/>All electronic reports were inspected by the principal reviewer (SP) and re-inspected by a second reviewer (MRB) in order to ensure reliable selection. We resolved any disagreement by discussion, and where there was still doubt we acquired the full article for further inspection. Once the full articles were obtained, we decided whether the studies met the review criteria. Whenever we could not resolve any disagreement by discussion, we sought further information from the authors and added these trials to the list of those awaiting assessment.</P>
<P>2. Assessment of quality <BR/>Again working independently, we allocated trials to three quality categories, as described in The Cochrane Collaboration Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Concealment of allocation remains the key aspect of methodology that predicts how susceptible results are to the inclusion of bias. Although adherence to blinding at outcome is also important, it is the ability of everyone involved to predict who will receive the next intervention that most substantially influences results. Category A studies in this review, where good concealment of allocation was made explicit, employed techniques that ensured that researchers and recipients could not have known the next intervention to be used. These studies would be considered at low risk of bias. Any plausible bias was felt to be unlikely to seriously affect results. Category B studies assured the reader that studies was randomized, but did not make concealment of allocation explicit. These studies were included but were at moderate risk of bias with some doubt raised about the results. Category C studies, where the process of allocation is neither described nor implied were not included. These studies are at high risk of bias and the plausible bias seriously weakens confidence in the results. </P>
<P>When disputes arose as to which category a trial was to be allocated, we attempted resolution by discussion. When this was not possible, only studies of possible Category C were excluded until further details became available. We only included trials in Category A or B in the review. We did not consider other dimensions of quality. </P>
<P>3. Data management <BR/>3.1 Data extraction <BR/>We independently extracted data from selected trials. When disputes arose resolution was attempted by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added this outcome of the trial to the list of those awaiting assessment.</P>
<P>3.2 Intention to treat analysis <BR/>We excluded data from studies where more than 50% of participants in any group were lost to follow up. In studies with less than 50% dropout rate, people leaving early were considered to have had the negative outcome, except for adverse effects such as death.</P>
<P>The impact of including studies with high attrition rates (25-50%) was to have been analysed in sensitivity analyses. If inclusion of data from this group did result in a substantive change in the estimate of effect of the primary outcomes, data from these studies were not to have been added to trials with less attrition, but presented separately. </P>
<P>4. Data analysis <BR/>4.1 Binary data <BR/>For binary outcomes we calculated a standard estimation of the fixed effects risk ratio (RR) and its 95% confidence interval (CI). Where possible, we would have calculated the number needed to treat/harm statistic (NNT/H), and its 95% confidence interval (CI), using Visual Rx (http://www.nntonline.net/) which takes account of the event rate in the relevant control group.</P>
<P>4.2 Continuous data <BR/>4.2.1 Skewed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to all data before inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale started from the finite number zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); (c) if a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied to them. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale), it is difficult to tell whether data are non-normally distributed (skewed) or not. Skewed data from studies of less than 200 participants would have been entered in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large and would have been entered into a synthesis.</P>
<P>4.2.2 Summary statistic: for continuous outcomes we would have estimated a fixed effects weighted mean difference (WMD) between groups. </P>
<P>4.2.3 Valid scales: we only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>) and the instrument was either a self-report or completed by an independent rater or relative (not the therapist). </P>
<P>4.2.4 Endpoint versus change data: We found it preferable to use scale end point data, which typically cannot have negative values and is somewhat easier to interpret from a clinical point of view. Change data are often not ordinal and interpretation is very problematic. If end point data were not available, we would have used change data.</P>
<P>4.2.5 Cluster trials: studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated, causing type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). </P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect. </P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation co-efficient (ICC) Design effect = 1+(m-1)*ICC (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>). </P>
<P>If cluster studies had been appropriately analysed taking into account intra-class correlation co-efficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>5. Investigation for heterogeneity<BR/>Firstly, consideration of all the included studies within any comparison was undertaken to estimate clinical heterogeneity. Then visual inspection of graphs was used to investigate the possibility of statistical heterogeneity. This was supplemented, primarily, by employing the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate included 75% this was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Data were then re-analysed using a random effects model to see if this made a substantial difference. If it did, and results became more consistent, i.e. falling below 75% in the estimate, the studies were added to the main body of trials. If using the random effects model did not make a difference and inconsistency remained high, data were not summated, but were presented separately and reasons for heterogeneity investigated.</P>
<P>6. Addressing publication bias <BR/>We would have entered all data in any included studies into a funnel graph (trial effect against trial size) in an attempt to investigate the likelihood of overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). </P>
<P>7. Sensitivity analyses <BR/>Where a trial was described as 'double-blind' but implied that the study was randomised, these trials were included in a sensitivity analysis. If there were no substantive differences within primary outcomes when these 'implied randomisation' studies were added, then they were included in the final analysis. However, if there was a substantive difference then only clearly randomised trails were used. The effect of including studies with high attrition rates (25-50%) will be analysed in sensitivity analyses. If inclusion of data from this group does result in a substantive change in the estimate of effect of the primary outcomes, data from these studies will be presented separately. A sensitivity analysis on the primary outcomes of this review (see Types of Outcomes) was conducted in order to investigate if this hierarchy of definition made any difference.</P>
<P>8. General <BR/>Where possible, reviewers entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for the intervention.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-31 10:54:55 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-31 10:54:55 +0000" MODIFIED_BY="[Empty name]">
<P>1. Excluded studies<BR/>The search of Cochrane Schizophrenia Group's register identified a total of 98 published references. We rejected 69 references as not relevant on the basis of information provided in the title and abstract. We obtained full text copies of the selected papers for the remaining 29 references. We also contacted the authors and were able to obtain a further four study papers.</P>
<P>Using a hierarchical approach to inclusion/exclusion (i.e. appropriate study design, followed by participants, intervention, outcome, in that order), we excluded the studies for the following reasons:</P>
<P>1.1 Study is not a randomised controlled trial<BR/>We excluded four studies as they were not randomised controlled studies (<LINK REF="STD-Avila-2003" TYPE="STUDY">Avila 2003</LINK>, <LINK REF="STD-Depatie-2002" TYPE="STUDY">Depatie 2002</LINK>, <LINK REF="STD-Myers-2004" TYPE="STUDY">Myers 2004</LINK>, Sherr 2002). All these were experimental trials studying effects of nicotine on saccadic eye movements or pursuit eye movements or delayed recognition in people with schizophrenia.</P>
<P>The following 11studies were classified as 'probably randomised' as this was not well described in the study design or allocation procedure (<LINK REF="STD-Dalack-1998" TYPE="STUDY">Dalack 1998</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Mead2" TYPE="STUDY">Dalack GW, Mead2</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Mead3" TYPE="STUDY">Dalack GW, Mead3</LINK>, <LINK REF="STD-Depatie-2001" TYPE="STUDY">Depatie 2001</LINK>, <LINK REF="STD-McEvoy-1997" TYPE="STUDY">McEvoy 1997</LINK>, <LINK REF="STD-Postma-2000" TYPE="STUDY">Postma 2000</LINK>, <LINK REF="STD-Smith-1998" TYPE="STUDY">Smith 1998</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, <LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>, <LINK REF="STD-Smith-R-C_x002c_-Ali-2" TYPE="STUDY">Smith R C, Ali 2</LINK>, <LINK REF="STD-Ziedonis-DM_x002c_-Ha2" TYPE="STUDY">Ziedonis DM, Ha2</LINK>). We did not exclude these studies at this stage but they were excluded later for different reasons (see below).</P>
<P>1.2 Study participants are not appropriate<BR/>One study had normal healthy volunteers and patients with schizophrenia ( <LINK REF="STD-Myers-2001" TYPE="STUDY">Myers 2001</LINK>). Although we did not exclude this study at this stage, it had to be excluded later as no useful data was available (see below).</P>
<P>1.3 Study interventions are not appropriate<BR/>We excluded these four studies as the intervention studied was not nicotine (<LINK REF="STD-George-2000" TYPE="STUDY">George 2000</LINK>, <LINK REF="STD-Marx-1997" TYPE="STUDY">Marx 1997</LINK>, <LINK REF="STD-McEvoy-1995" TYPE="STUDY">McEvoy 1995</LINK>, <LINK REF="STD-Ziedonis-DM_x002c_-Ha2" TYPE="STUDY">Ziedonis DM, Ha2</LINK>)</P>
<P>1.4 Study outcomes are not usable<BR/>We excluded the following three studies as outcomes were not clinically relevant. (<LINK REF="STD-Abbas-2004" TYPE="STUDY">Abbas 2004</LINK>, <LINK REF="STD-Donnelly-1996" TYPE="STUDY">Donnelly 1996</LINK>, <LINK REF="STD-Postma-2000" TYPE="STUDY">Postma 2000</LINK>)</P>
<P>1.5 Study results are not usable<BR/>We excluded the following sixteen studies as outcome results were not given.(<LINK REF="STD-Bustillo-2001" TYPE="STUDY">Bustillo 2001</LINK>, <LINK REF="STD-Chou-2004" TYPE="STUDY">Chou 2004</LINK>, <LINK REF="STD-Dalack-1996" TYPE="STUDY">Dalack 1996</LINK>, <LINK REF="STD-Dalack-1997" TYPE="STUDY">Dalack 1997</LINK>, <LINK REF="STD-Dalack-1998" TYPE="STUDY">Dalack 1998</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Beck2" TYPE="STUDY">Dalack GW, Beck2</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Beck3" TYPE="STUDY">Dalack GW, Beck3</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Mead2" TYPE="STUDY">Dalack GW, Mead2</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Mead3" TYPE="STUDY">Dalack GW, Mead3</LINK>, <LINK REF="STD-Depatie-2001" TYPE="STUDY">Depatie 2001</LINK>, <LINK REF="STD-McEvoy-1997" TYPE="STUDY">McEvoy 1997</LINK>, <LINK REF="STD-Myers-2001" TYPE="STUDY">Myers 2001</LINK>, <LINK REF="STD-Smith-1998" TYPE="STUDY">Smith 1998</LINK>, <LINK REF="STD-Smith-2000" TYPE="STUDY">Smith 2000</LINK>, <LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>, <LINK REF="STD-Smith-R-C_x002c_-Ali-2" TYPE="STUDY">Smith R C, Ali 2</LINK>).</P>
<P>We excluded another six studies as they were all of crossover design and after contacting the authors no further data were available at the point of crossover (<LINK REF="STD-Dalack-1999" TYPE="STUDY">Dalack 1999</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Mead4" TYPE="STUDY">Dalack GW, Mead4</LINK>, <LINK REF="STD-Levin-1996" TYPE="STUDY">Levin 1996</LINK>, <LINK REF="STD-Smith-2001" TYPE="STUDY">Smith 2001</LINK>, <LINK REF="STD-Smith-2002" TYPE="STUDY">Smith 2002</LINK>, <LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>)</P>
<P>2. Included studies<BR/>No studies met the inclusion criteria for this study.</P>
<P>3. Studies awaiting assessment<BR/>No studies are awaiting assessment.</P>
<P>4. Ongoing<BR/>We are not aware of any relevant ongoing studies</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No studies fulfilled the criteria for inclusion.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search<BR/>The Cochrane Schizophrenia Group's register is the most comprehensive trials register of its kind, yet no trials met the inclusion criteria.</P>
<P>2. Excluded studies<BR/>Closer inspection of the 33 excluded studies for which we obtained papers, suggests that our entry criteria were not too restrictive. Apart from reasons of no randomisation and irrelevant interventions or outcomes, we excluded sixteen studies as there were no data available despite contacting the authors. An example of such a study is <LINK REF="STD-Bustillo-2001" TYPE="STUDY">Bustillo 2001</LINK>, which is entirely appropriate for this review, but no trial data were available. We also had to exclude another six trials as they were of a crossover type design which was not appropriate for this review.</P>
<P>3. The data on nicotine versus any treatment for schizophrenia<BR/>There are no included studies.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Many of the trials we reviewed were of a crossover design. Crossover study data are not appropriate for meta-analysis purposes as detailed in <LINK REF="REF-Fleiss-1989" TYPE="REFERENCE">Fleiss 1989</LINK> and <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>. Professor Elbourne has later confirmed to us that crossover design is not appropriate if the condition is unstable and there are likely to be carryover effects. Schizophrenia is an unstable condition and nicotine is likely to have carryover effects.</P>
<P>2. Although individual studies report effects of nicotine on symptoms of Schizophrenia (<LINK REF="STD-Dalack-1999" TYPE="STUDY">Dalack 1999</LINK>, <LINK REF="STD-Dalack-GW_x002c_-Mead4" TYPE="STUDY">Dalack GW, Mead4</LINK>, <LINK REF="STD-Smith-2001" TYPE="STUDY">Smith 2001</LINK>, <LINK REF="STD-Smith-2002" TYPE="STUDY">Smith 2002</LINK>) or as modifying side effects of antipsychotic medication (<LINK REF="STD-Levin-1996" TYPE="STUDY">Levin 1996</LINK>, <LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>), the validity of these results cannot be confirmed within a meta-analysis.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For patients with schizophrenia<BR/>People with schizophrenia smoke in very high proportions. Unfortunately, due to the lack of included studies in this review, we cannot explain why this strong association exists and whether nicotine modifies symptoms of schizophrenia or side effects of antipsychotic medication.</P>
<P>2. For clinicians<BR/>Even though the question of nicotine in relation to its effects on schizophrenia is of an experimental nature, it is nevertheless important due to the profound adverse health and social consequences of smoking in patients with schizophrenia.</P>
<P>3. For policy-makers<BR/>Before developing services or interventions to help smoking cessation in schizophrenia, we need to have a clear understanding of whether nicotine alters symptoms of schizophrenia or side effects of antipsychotic medication in any way. If nicotine is effective in improving symptoms of schizophrenia, then it raises the interesting question as to whether nicotine products (patches, sprays or gums) should be prescribed to patients with schizophrenia.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>If the excluded studies had all the data available, we would at least have some hypothesis generating data on the effects of nicotine for schizophrenia. Future studies and journals should comply with CONSORT recommendations.</P>
<P>2. Specific<BR/>There is a need for randomised controlled trials investigating the effects of nicotine (administered as patches, gums or inhaler) for schizophrenia. These trials ought to be of a parallel design of longer duration (at least four to six weeks), having groups receiving nicotine versus placebo, either with or without antipsychotic drugs. Trials are also needed to investigate the effect of nicotine in modifying side effects of antipsychotic drugs, this can be studied with a parallel design RCT with groups receiving nicotine or placebo while taking antipsychotics. These trials must report all the data available on positive symptoms, negative symptoms, cognitive symptoms and side effects.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-11-03 14:57:42 +0000" MODIFIED_BY="[Empty name]">
<P>1. Professor Clive Adams, Division of Psychiatry, University of Leeds, UK - for his continued support and encouragement at all stages while we conducted this review.<BR/>2. Professor Diana Elbourne, Medical Statistics Unit, London School of Hygiene and Tropical Medicine, UK - for her prompt response in clarifying usefulness of data from crossover trials</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>We know of no conflicts of interest. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Sumir Punnoose - instigated the review, developed the protocol, and wrote the full review</P>
<P>Madhvi Belgamwar - helped to develop the protocol and the review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Abbas-2004" NAME="Abbas 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Abbas A, Hong E, Avila M, Thaker G</AU>
<TI>Effects of nicotine on prepulse inhibition in schizophrenia</TI>
<SO>157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA</SO>
<YR>2004</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="APA Conference Abstracts NR68"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Avila-2003" NAME="Avila 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avila MT, Sherr JD, Hong E, Myers CS, Thaker GK</AU>
<TI>Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>2184-191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bustillo-2001" NAME="Bustillo 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bustillo JR</AU>
<TI>Nicotine treatment for schizophrenia</TI>
<SO>National Alliance for Research on Schizophrenia and Depression (http:, www.mhsource.com/narsad/bd/schres_abc.html accessed February 2001)</SO>
<YR>2001</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99079075"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9862082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chou-2004" NAME="Chou 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou K, Chen R, Lee J, Ku C, Lu R</AU>
<TI>The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia</TI>
<SO>International Journal of Nursing Studies</SO>
<YR>2004</YR>
<VL>41</VL>
<NO>3</NO>
<PG>321-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CINAHL 2004097114"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-1996" NAME="Dalack 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dalack GW, Becks LM, Hill EM, Pomerleau O, Meador-Woodruff JH</AU>
<TI>Nicotine withdrawal and psychiatric symptoms in smokers with schizophrenia</TI>
<SO>149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76020495"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 54-08048; PMID 1100217"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-1997" NAME="Dalack 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalack GW, Becks L, Hill E, Pomerleau O, Meador-Woodruff JH</AU>
<TI>The effects of treated and untreated nicotine withdrawal in smokers with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>2</NO>
<PG>63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76020495"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 54-08048; PMID 1100217"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-1998" NAME="Dalack 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalack GW, McDaniel D, Meador-Woodruff JH</AU>
<TI>Effects of nicotine on dyskinesias in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>121S-22S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14033"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-1999" NAME="Dalack 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalack GW, Becks L, Hill E, Pomerleau of, Meador-Woodruff JH</AU>
<TI>Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>2</NO>
<PG>195-202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99361032"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 10432467"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-GW_x002c_-Beck2" NAME="Dalack GW, Beck2" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dalack GW, Becks L, Hill E, Pomerleau O, Meador-Woodruff JH</AU>
<TI>Nicotine withdrawal and replacement in schizophrenia</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70116032"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4906138"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-GW_x002c_-Beck3" NAME="Dalack GW, Beck3" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dalack GW, Becks L, Hill E, Pomerleau O, Meador-Woodruff JH</AU>
<TI>Nicotine withdrawal and replacement in schizophrenia</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70116032"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4906138"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-GW_x002c_-Mead2" NAME="Dalack GW, Mead2" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dalack GW, Meador-Woodruff JH</AU>
<TI>The nicotine patch, smoking and schizophrenia</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68001338"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4292729"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-GW_x002c_-Mead3" NAME="Dalack GW, Mead3" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalack GW, Meador-Woodruff JH</AU>
<TI>Nicotine replacement and smoking reduction in smokers with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>36</VL>
<PG>276</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99079075"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9862082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-GW_x002c_-Mead4" NAME="Dalack GW, Mead4" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalack GW, Meador-Woodruff JH</AU>
<TI>Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia</TI>
<SO>Nicotine and Tobacco Research</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>53-7</PG>
<PB>Carfax Publishing.</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 2000-14188-004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Depatie-2001" NAME="Depatie 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Depatie L, O'Driscoll GA, Wolff AV, Atkinson V, Thavundayil J, Ng Yin Kin N, Lal S</AU>
<TI>Effect of nicotine on attention and oculomotor tasks in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>2</NO>
<PG>213-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 2000-14188-004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Depatie-2002" NAME="Depatie 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Depatie L, O'Driscoll GA, Holahan AV, Atkinson V, Thavundayil JX, Kin NY, Lal S</AU>
<TI>Nicotine and behavioural markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1056-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donnelly-1996" NAME="Donnelly 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donnelly CL, McEvoy JP, Wilson WH, Narasimhachari N</AU>
<TI>A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with Schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>12</NO>
<PG>1218-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97118435"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1997-08155-004; PMID 8959286"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-George-2000" NAME="George 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR</AU>
<TI>Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>11</NO>
<PG>1835-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2000389156"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-1996" NAME="Levin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin ED, Wilson W, Rose JE, McEvoy J</AU>
<TI>Nicotine-haloperidol interactions and cognitive performance in schizophrenics</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>5</NO>
<PG>429-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1996355126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marx-1997" NAME="Marx 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marx CE, McEvoy JP</AU>
<TI>The effect of mecamylamine on smoking patterns in psychiatric patients</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70252387"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4914870"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-1995" NAME="McEvoy 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy J, Freudenreich O, McGee M, Vander-Zwaag C, Levin E, Rose J</AU>
<TI>Clozapine decreases smoking in patients with chronic schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>8</NO>
<PG>550-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95345266"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7619979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-1997" NAME="McEvoy 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McEvoy JP, Levin E, Rose J</AU>
<TI>Effects of antipsychotic drugs on smoking</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92021363"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1924667"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myers-2001" NAME="Myers 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Myers CS, Sherr JD, Kakoyannis A, Robles O, Thaker GK, Blaxton TA</AU>
<TI>Effects of nicotine on memory and attention in schizophrenia.</TI>
<SO>31st Annual Meeting of the Society for Neuroscience; 2001 Nov 10-15; California, USA</SO>
<YR>2001</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Biological Abstracts 00476838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myers-2004" NAME="Myers 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myers CS, Robles O, Kakaoyannis AN, Sherr JD, Avila MT, Blaxton TA, Thaker GK</AU>
<TI>Nicotine improves delayed recognition in schizophrenic patients</TI>
<SO>Psychopharmacology</SO>
<YR>2004</YR>
<VL>174</VL>
<PG>334-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Postma-2000" NAME="Postma 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Postma P, Gray JA, Kumari V, Soni W, Zachariah E, Mehtrora R, Das M, Hines M, Sharma T</AU>
<TI>Effects of nicotine on prepulse inhibition in schizophrenic patients</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S109</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01065"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherr--2002" NAME="Sherr  2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK</AU>
<TI>Effects of nicotine on specific eye tracking measures in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2002</YR>
<VL>52</VL>
<PG>721-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1998" NAME="Smith 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Smith RC, Nigam S, Ali A</AU>
<TI>Effects of smoking on positive and negative symptoms and neurocognitive function in schizophrenia</TI>
<SO>21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67220871"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5341425"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2000" NAME="Smith 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Singh AK, Infante M, Khandat A, Samimy S</AU>
<TI>Effects of cigarette smoking and nicotine nasal spray on negative and positive symptoms and neurocognitive functioning in schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S118</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2001" NAME="Smith 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Infante M, Ali A, Nigam S, Kotsaftis A</AU>
<TI>Effects of cigarette smoking on psychopathology scores in patients with schizophrenia: an experimental study</TI>
<SO>Substance Abuse</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>3</NO>
<PG>175-186</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CINAHL 2002023859"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2002" NAME="Smith 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Singh A, Infante M, Khandat A, Kloos A</AU>
<TI>Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>3</NO>
<PG>479-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="BIOSIS 00523161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2003" NAME="Smith 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Singh A, Khandat A, Infante M, Warner-Cohen J</AU>
<TI>Effects of smoking and nicotine nasal spray on cognition and affect in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>International Congress on Schizophrenia Research 2003</VL>
<PG>316</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CENTRAL CN-00382502"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-R-C_x002c_-Ali-2" NAME="Smith R C, Ali 2" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Ali A, Nigam S</AU>
<TI>Effects of smoking on affect, cognition, and symptoms in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>115S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14033"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2002" NAME="Yang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP</AU>
<TI>Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>4</NO>
<PG>684-6</PG>
<PB>Elsevier Science, US</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziedonis-DM_x002c_-Ha2" NAME="Ziedonis DM, Ha2" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ziedonis DM, Harris SA, Wyatt P, Trudeau TP, George K, Johnson D</AU>
<TI>Motivational enhancement therapy and nicotine replacement improve smoking cessation outcomes</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73127297"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4569673"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Addington-1998" NAME="Addington 1998" TYPE="JOURNAL_ARTICLE">
<AU>Addington J. el-Guebaly N. Campbell W. Hodgins DC. Addington D</AU>
<TI>Smoking cessation treatment for patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>7</NO>
<PG>974-976</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 9659869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Adler-1993" NAME="Adler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Adler LE. Hoffer LD. Wiser A. Freedman</AU>
<TI>Normalization of auditory physiology by cigarette smoking in schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>12</NO>
<PG>1856-1861</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 8238642"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="OLZ020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-629</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dohrenwend-1980" NAME="Dohrenwend 1980" TYPE="BOOK">
<AU>Dohrenwend BP</AU>
<SO>Mental Illness in the United States. Epidemiologic Estimates</SO>
<YR>1980</YR>
<PB>Praeger</PB>
<CY>New York, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-2980</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-634</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analysis involving cross-over trials : Methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-149</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fenton-1997" NAME="Fenton 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fenton WS, Blyler CR, Heinssen RK</AU>
<TI>Determinants of medication compliance in schizophrenia: empirical and clinical findings</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>4</NO>
<PG>637-651</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9366000"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1989" NAME="Fleiss 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fleiss JL</AU>
<TI>A critique of recent reseach on the two-treatment crossover design</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>3</NO>
<PG>237-243</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glassman-1993" NAME="Glassman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Glassman AH</AU>
<TI>Cigarette smoking: implications for psychiatric illness</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>4</NO>
<PG>546-553</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 8465868"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-883</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="COCHRANE_REVIEW">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1986" NAME="Hughes 1986" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR. Hatsukami DK. Mitchell JE. Dahlgren LA</AU>
<TI>Prevalence of smoking among psychiatric outpatients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<NO>8</NO>
<PG>993-997</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 3487983"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jablensky-1992" NAME="Jablensky 1992" TYPE="JOURNAL_ARTICLE">
<AU>Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A</AU>
<TI>Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study</TI>
<SO>Psychological Medicine. Monograph Supplement</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>1-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2000" NAME="Kelly 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kelly C, McCreadie R</AU>
<TI>Cigarette smoking and schizophrenia</TI>
<SO>Advances in Psychiatric Treatment</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>327-331</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M.</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?;176:249-52.</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-252</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regier-1984" NAME="Regier 1984" TYPE="JOURNAL_ARTICLE">
<AU>Regier DA, Myers JK, Kramer M, Robins LN, Blazer DG, Hough RL, Eaton WW, Locke BZ</AU>
<TI>The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>10</NO>
<PG>934-941</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Young-1986" NAME="Young 1986" TYPE="JOURNAL_ARTICLE">
<AU>Young JL, Zonana HV, Shepler L</AU>
<TI>Medication noncompliance in schizophrenia: codification and update</TI>
<SO>Bulletin of the American Academy of Psychiatry and the Law</SO>
<YR>1986</YR>
<VL>14</VL>
<NO>2</NO>
<PG>105-122</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ziedonis-1997" NAME="Ziedonis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ziedonis DM. George TP</AU>
<TI>Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>2</NO>
<PG>247-254</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 9165635"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abbas-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: nicotine vs placebo.<BR/>Outcomes: prepulse inhibition, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Avila-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: nicotine nasal spray vs placebo.<BR/>Outcomes: eye movements, no usable data.<BR/>Author kindly replied and no futher data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bustillo-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: nicotine vs placebo pathes.<BR/>Outcomes: unclear no usable data. <BR/>Author not replied</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chou-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: nicotine patch vs placebo.<BR/>Outcomes: Smoking cessation measures, no usable data of psychiatric symptoms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover design<BR/>Participants: people with schizophrenia.<BR/>Interventions: nicotine patch vs placebo.<BR/>Outcomes: no usable data<BR/>Author has kindly replied, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossver design<BR/>Participants: with schizophrenia <BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no usable data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: describes 2 studies, randomisation unclear<BR/>Participants: with schizophrenia <BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: abnormal involuntary movement scores<BR/>Author contacted, no usable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossver design<BR/>Participants: with schizophrenia &amp; scizoaffective disorder<BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-GW_x002c_-Beck2">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossver design<BR/>Participants: with schizophrenia &amp; scizoaffective disorder<BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-GW_x002c_-Beck3">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossver design<BR/>Participants: with schizophrenia &amp; scizoaffective disorder<BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-GW_x002c_-Mead2">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomisation unclear, crossover design<BR/>Participants: with schizophrenia<BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-GW_x002c_-Mead3">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomisation unclear, crossver design<BR/>Participants: with schizophrenia <BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-GW_x002c_-Mead4">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised, crossver design<BR/>Participants: with schizophrenia &amp; scizoaffective disorder<BR/>Interventions: nicotine vs placebo patches<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Depatie-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised, has a crossover design<BR/>Participants: people with schizophrenia and normal controls<BR/>Interventions: nicotine patch<BR/>Outcomes: clinically not important measures, no usable data Author kindly replied and no further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Depatie-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised, has a crossover design<BR/>Participants: people with schizophrenia and normal controls<BR/>Interventions: nicotine patch<BR/>Outcomes: clinically not important measures, no usable data Author kindly replied and no further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Donnelly-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: with schizophrenia and schizoaffective disorder<BR/>Interventions: smoking cigarettes vs cola drink vs none<BR/>Outcomes: homovanillic acid levels, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-George-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: block randomised.<BR/>Participants: with scizophrenia and schizoaffective disorder<BR/>Interventions: standard vs intensive group therapy<BR/>Outcomes: smoking cessation outcomes, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover type, methodology unclear<BR/>Participants: people with schizophrenia.<BR/>Interventions: after haloperidol, nicotine vs placebo patches<BR/>Outcomes: cognitive tests, No usable data<BR/>No available data showing how many allocated to each arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marx-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: with schizophrenia mania and subtance misuse.<BR/>Interventions: low vs high dose tablets of Mecamylamine<BR/>Outcomes: smoking cessation outcomes, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McEvoy-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: low vs moderate vs high doses of clozapine<BR/>Outcomes: psychiatric and smoking scales, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McEvoy-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: varying doses of haloperidol followed by Nicotine<BR/>Outcomes: cognitive impairments, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Myers-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and normal volunteers<BR/>Interventions: nicotine nasal spray<BR/>Outcomes: memory and attention, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Myers-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised (probably not)<BR/>Participants: people with schizophrenia.<BR/>Interventions: nicotine nasal spray<BR/>Outcomes: delayed recognition (&amp; memory), no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Postma-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: subcutaneous injection of nicotine vs saline<BR/>Outcomes: prepulse inhibition, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sherr--2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised (probably not)<BR/>Participants: people with schizophrenia and normal volunteers.<BR/>Interventions: nicotine nasal spray<BR/>Outcomes: Specific Eye Tracking measures, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised<BR/>Participants: patients with schizophrenia <BR/>Interventions: high vs low dose nicotine cigarettes<BR/>Outcomes: psychiatric outcomes, data not available<BR/>Author contacted, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised, crossover design<BR/>Participants: patients with chronic schizophrenia <BR/>Interventions: strong &amp; mild cigarettes, active &amp; placebo spray<BR/>Outcomes: psychiatric &amp; smoking outcomes, no usable data<BR/>Author contacted, no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: Randomised, crossover design<BR/>Participants: with schizophrenia and schizoaffective disorder<BR/>Interventions: high vs low dose nicotine cigarettes<BR/>Outcomes: psychiatric outcomes (PANSS, SANS)<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover design<BR/>Participants: with schizophrenia and schizoaffective disorder<BR/>Interventions: strong &amp; mild cigarettes, active &amp; placebo spray<BR/>Outcomes: psychiatric and smoking cessation outcomes<BR/>Author contacted, no further data at the point of crossover</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised<BR/>Participants: people with schizophrenia.<BR/>Interventions: strong &amp; mild cigarettes, active &amp; placebo spray<BR/>Outcomes: psychiatric outcomes, no available data<BR/>Author contacted, no further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-R-C_x002c_-Ali-2">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised<BR/>Participants: people with schizophrenia.<BR/>Interventions: low vs high content nicotine cigarettes<BR/>Outcomes: psychiatric outcomes, no available data<BR/>Author contacted, no further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover type, methodology unclear<BR/>Participants: people with schizophrenia.<BR/>Interventions: after haloperidol, nicotine vs placebo patches<BR/>Outcomes: psychiatric outcomes - BPRS, EPS, No usable data<BR/>Author contacted, no available data showing how many allocated to each arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ziedonis-DM_x002c_-Ha2">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised<BR/>Participants: people with schizophrenia.<BR/>Interventions: once vs twice weekly psychosocial treatments<BR/>Outcomes: smoking cessation outcomes, no usable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>